HLHe Li

He Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


He Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Tong Wu

    Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

    3 shared publications
  • Yibin Hu

    Neurology Department of The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, 250355, PR China

    3 shared publications
  • Dingwen Yu

    Muping osteopathy hospital, Yantai City, China

    2 shared publications
  • Gehui Jia

    Shandong University of Traditional Chinese Medicine, Jinan, China

    2 shared publications
  • Haixuan Zhang

    Neurology Department of The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan City, China

    2 shared publications
  • Jiawei Wang

    Shandong University of Traditional Chinese Medicine, Jinan, China

    2 shared publications

Latest Publications

  • Efgartigimod Alfa as a novel rescue therapy for severe NMOSD: a case report

    by Yundi Wei, Cuilan Wang, Xiangqing Xu, Hengye Zhao, Dingwen Yu, He Li, Tong Wu

  • Open Access

    Treatment of internal carotid artery agenesis with intercavernous anastomosis (Lie’s type D anastomosis) by simple balloon dilatation

    by ZunLu Zhang, JinPing Zhang, Dingwen Yu, He Li

    This article reports a rare vascular anomaly: internal carotid artery agenesis with intercavernous anastomosis (Lie’s type D anastomosis). According to Digital Subtraction Angiography (DSA), the left common carotid artery (LCCA) continues as the external carotid artery (ECA), and no lumen arteriosclerosis or the origin of the internal carotid artery (ICA) is observed on the angiogram. The patient’s left internal carotid artery (LICA) originated from the C6 segment of the right internal carotid artery and was compensated by it. At the same time, both the left middle cerebral artery(LMCA) and the anterior cerebral artery(ACA) originates from the right internal carotid artery (RICA) system. Severe stenosis at the beginning of LICA resulted in TIA in patients. After simple balloon dilation treatment, the patient showed favorable angioplasty and no further ischemic events occurred during a 1-year follow-up. Previous such studies have less experience with previous involvement. This article suggests that simple balloon dilation may effectively improve the prognosis of patients with vascular anomaly accompanied by severe stenosis, with low risk. This has certain teaching and clinical guidance value.

  • Neixiao-ruanmai decoction No 2 improves carotid atherosclerosis by modulating gut microbiota and inhibiting TLR4/NF-κB pathway activation

    by Hanrui Ji, Zhizhi Dong, Yanan Yang, Wenqiang Cui, Jingbo Han, Yibin Hu, Haonan Chen, Chongxuan Qiao, Qingxiao Li, He Li, et al.


  • Open Access

    Efficacy and Safety of Various Intravenous Thrombolytics for Acute Ischemic Stroke (AIS) at Various Dosages: A Systematic Review and Network Meta-Analysis

    by Yibin Hu, Shengxian Wu, Haixuan Zhang, Kangfeng Wang, Lijuan Zhang, Yizheng Ma, He Li

    Background Currently, there is limited evidence on the efficacy and safety of various thrombolytic drugs at different dosages for the treatment of acute ischemic stroke (AIS). From current randomized clinical trials, the optimal type and dosage of thrombolytics for patients with AIS are unclear. Methods This systematic review was registered in PROSPERO (CRD42024563757). We searched four databases using a combination of keywords that contained various intravenous thrombolytics, as well as acute ischemic stroke. Only data from participants with AIS treated with various intravenous thrombolytics within the 4.5-h time window were included. Among initially identified studies, 16 met the selection criteria. Network meta-analysis was conducted for efficacy (90 day modified Rankin scale score) and safety (intracranial hemorrhage events, mortality at 90 days) using Stata 17.0 software, with a fixed-effects model. Cochrane risk of bias tool assessed all risk of bias domains, and the CINeMA Evidence Assessment Tool evaluated the level of evidence for each outcome. Results A total of 9056 studies were retrieved through the literature search, and 12,792 patients screened from 16 randomized controlled trials were included in the network meta-analysis. The risk of bias in the included studies ranged from moderate to low. The network meta-analysis results indicated that reteplase at 18 + 18 mg ranked highest in efficacy, though its safety was lower compared to 0.25 mg/kg tenecteplase and alteplase. The dose of 0.25 mg/kg tenecteplase emerged as the optimal dose, demonstrating both superior efficacy and a lower risk of bleeding compared to alteplase, making it a potential alternative to alteplase. The dose of 50 mg prourokinase was associated with the highest risk of symptomatic intracranial hemorrhage and was inferior to reteplase in terms of both efficacy and safety. The CINeMA Evidence Assessment Tool identified one outcome with a high level of evidence, several with moderate levels, and the remainder with low levels. Conclusions Reteplase at 18 + 18 mg may be more suitable for patients with lower incidence of adverse events evaluated by physicians. Compared to 0.9 mg/kg alteplase, 0.25 mg/kg tenecteplase is more effective, with the lowest risk of intracranial hemorrhage. However, as tenecteplase’s dosages increase (0.32 mg/kg and 0.4 mg/kg), its efficacy in improving neurological deficits decreases, while the risk of intracranial hemorrhage and death (especially at 0.4 mg/kg) increases. Clinicians are supposed to carefully assess the needs of patients with AIS and the risks then choose decent thrombolytics.


  • Reversible cerebral vasoconstriction syndrome and bilateral Eagle Syndrome cause recurrent reversible carotid artery stenosis and cerebral infarction

    by Qi Chao, Pingping Wang, He Li

    A middle-aged male who has experienced recurrent, reversible carotid artery stenosis and cerebral infarction over the past decade. Recurrent cerebral infarction is highly prevalent in clinical practice, with an accurate diagnosis of the cause of the disease being crucial. However, the patient is suffering from three diseases that may be involved in the recurrent cerebral infarction, including Reversible Cerebral Vasoconstriction Syndrome (RCVS), Bilateral Eagle Syndrome, and Patent Foramen Ovale (PFO). Among them, both RCVS and Bilateral Eagle Syndrome can lead to recurrent stenosis of the carotid arteries. But the coexistence of these diseases is extremely rare. The symptoms of patients are not typical, and the coexistence of all the three diseases makes it a challenging diagnostic dilemma. This article presents a diagnostic approach to differentiate these possible diseases, thereby enhancing readers’ ability to diagnose such situations.

  • Open Access

    Correlation Between Regulation of Intestinal Flora by Danggui‐Shaoyao‐San and Improvement of Cognitive Impairment in Mice With Alzheimer's Disease

    by Ya‐Han Wang, Peng‐Li Ding, Kai‐Xin Zhang, Xiang‐Qing Xu, He Li

    Purpose: The abnormal central glucose metabolism in Alzheimer's disease (AD) is related to the brain–gut axis. This study aims to explore the target of Danggui‐Shaoyao‐San (DSS) in improving cognitive impairment.Method: This study analyzed the differences in mice intestinal flora by 16S rRNA sequencing. The cognitive protective effects of DSS were observed through the Morris water maze and the new object recognition. The mitigation effects of DSS on Aβ and p‐tau, regulatory effects on glucose metabolism targets, and intestinal structure effects were observed through brain and colon slices staining. The differences in neural ultrastructure were compared by transmission electron microscopy.Finding: The results showed that DSS affected the composition of intestinal dominant bacteria and bacteria genera and regulated the abundance of intestinal bacteria in AD mice. DSS improved the behavior of AD mice, alleviated the deposition of AD pathological products in the brain and colon, regulated the expression of glycometabolism‐related proteins, and improved the colon barrier structure and neural ultrastructure in the brain of mice with AD.Conclusion: Our findings suggest that DSS may affect AD central glucose metabolism and improve cognition by regulating the gut–brain axis.


  • Open Access

    Research progress of Ganoderma lucidum polysaccharide in prevention and treatment of Atherosclerosis

    by YiZheng Ma, JingBo Han, KangFeng Wang, Huan Han, YiBin Hu, He Li, ShengXian Wu, LiJuan Zhang


  • Open Access

    Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis

    by YiRan Cheng, ChangNing Liu, ShanShan Li, Miao Miao Meng, He Li

    Objective: Argatroban is a highly promising drug for the treatment of acute ischemic stroke (AIS), but there is currently insufficient strong evidence regarding the efficacy and safety of using Argatroban in the treatment of AIS. Therefore, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of Argatroban in the treatment of AIS.Methods: Articles on PubMed, Embase and the Cochrane Library databases were searched from these websites’ inceptions to 2th February 2023. Randomized controlled trials and observational studies on Argatroban therapy for acute ischemic stroke were included. Meta-analyses were conducted using a random-effects model.Results: Fourteen studies involving 10,315 patients were included in the meta-analysis. The results showed a significant reduction in the rate of early neurological deterioration (END) in the Argatroban group compared with the control group (OR = 0.47, 95% CI: 0.31–0.73, I2 = 15.17%). The rates of adverse events were no significant difference between the two groups (ICH: OR = 1.02, 95% CI: 0.68–1.51, I2 = 0.00%; major extracranial bleeding: OR = 1.22, 95% CI: 1.01–1.48, I2 = 0.00%; mortality: OR = 1.16, 95% CI: 0.84–1.59, I2 = 0.00%). However, the rates of mRS score of 0–1 (OR = 1.38, 95% CI: 0.71–2.67, I2 = 77.56%) and mRS score of 0–2 (OR = 1.18, 95% CI: 0.98–1.42, I2 = 0.00%) during the 90 days did not significantly improved in the Argatroban group. Subgroup analyses showed that the rate of END (OR = 0.41, 95% CI: 0.26–0.65, I2 = 2.77%) and mRS score of 0–2 (OR = 1.38, 95% CI: 1.06–1.81, I2 = 0.00%) had significantly improved when the intervention group adopted Argatroban plus Antiplatelet.Conclusion: Argatroban can improve neurological deterioration, with a low incidence of adverse events such as bleeding and death, and general analysis showed no improvement in mRS. However, subgroup analysis suggests that compared to mono-antiplatelet therapy, combination therapy of Argatroban combined with antiplatelet therapy significantly reduced the incidence of END and improved mRS scores. After using Argatroban, there was no increase in the risk and mortality of intracranial hemorrhage and other bleeding sites.